Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
BURLINGTON, Mass., March 03, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its year-end 2015 financial results on Thursday, March 10, 2016, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID # 53086231. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
